Facebook Tracking Image

National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Pfizer Axitinib Research Grant Opportunity: Submit by Wednesday, August 12, 2020
NCCN Pfizer Biosimilars Grant Opportunity - Submit by Wednesday, September 9, 2020
ORP Recent News
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees
NCCN Policy Priorities

NCCN Research & Business Resources

Stanford Cancer Institute (SCI)
Stanford University

Comprehensive Cancer Center

SCI Administration:

Adult Patient Care:
Pediatric Patient Care:

Stanford, CA

Find a clinical trial >



The Stanford Cancer Institute (SCI), located in the heart of Silicon Valley in California, is one of only 49 National Cancer Institute-Designated Comprehensive Cancer Centers in the country.  The SCI’s mission is to reduce cancer mortality through comprehensive programs of cancer research, treatment, education and outreach.  Stanford has a long tradition of innovation in cancer research and translational medicine. 

By leveraging the expertise of nearly 500 physicians and researchers, the SCI harnesses the vast intellectual and scientific resources of Stanford University, Stanford Health Care and Stanford Children’s Health to advance the understanding of cancer and rapidly translate those research discoveries into improved prevention strategies, novel diagnostics, and safer, more effective therapies.  Stanford’s cancer treatment programs combine new advances in precision medicine with compassionate care and supportive services.


Investigators at Stanford are leading a revolution in cancer biology and transforming how we treat cancer patients.  The SCI has over 250 available clinical trials across all types of cancer and all phases of trials, including a rapidly growing Phase I clinical trials portfolio.  Stanford is committed to diversity and inclusion in its research and is very interested in partnering with communities to remove barriers to participation.

The SCI has particular scientific strengths in cancer cell and stem cell biology, radiation biology, genetics and genomics, immunology and immunotherapy, and molecular imaging.  Dating from the first use of the linear accelerator in 1955 and the pioneering work in the combined modality treatment of Hodgkin’s disease, Stanford has provided innovative ideas that have greatly advanced the diagnosis and treatment of a wide variety of cancers. Stanford faculty members have pioneered the development of genomic technologies, detection of circulating tumor DNA, and the application of monoclonal antibodies to cancer treatment, among many other major advances.

Programs and Initiatives

In addition to the eight research programs identified in our Cancer Center Support Grant, the Stanford Cancer Institute supports a number of key initiatives designed to foster discovery, application and translation of scientific knowledge.  Inter-disciplinary teams of collaborative investigators partner to solve some of the most challenging questions in cancer research and patient care. 

Some of our key initiatives include: 

  • Pioneering work in the fields of blood and marrow transplant and cancer cell therapy, including one of the first uses of a bivalent CAR-T cell therapy in patients
  • Large, multidisciplinary research and patient care programs in pancreas cancer and lung cancer
  • A dedicated Stanford Women’s Cancer Center focused on the treatment of breast and gynecologic cancers